Cell based therapy for vascular regeneration

Vascular endothelial stem cells (VESCs) based therapy is a promising approach for vascular regeneration.

Core Benefits

  • VESC based therapy will be able to offer long-lasting benefit for patients.
  • VESC based therapy will be applicable for many diseases, not only ischemic disease but also metabolic disease, other vascular diseases.


VESCs possess both self-renewal potential and various vessel formation capacity.

Researchers newly discovered a VESC and they identified CD157 and CD200 as markers of VESCs. CD200+CD157+VESCs differentiate into CD157CD200endothelial cell (ECs) through CD157CD200+ECs. CD157CD200+ECs also possess vessel formation capacity, but CD157CD200ECs were completely unable to contribute to new blood vessels. Therefore, VESCs maintain the vasculature by supplying terminally differentiating ECs.


Vascular ECs that line the inner surface of blood vessels are essential for maintenance of organ homeostasis and tissue regeneration. In 1997, the concept that endothelial progenitor cells (EPCs) participate in postnatal angiogenesis or vascular repair was proposed. EPCs based therapy have expected as a novel therapeutic therapy for various diseases.  However, it is known that the effect of EPCs in endothelial repair and angiogenesis is transient. Some reports suggest that the contribution of EPCs to the neovascular ECs itself is not sufficient (Gothert et al, 2004; Peters et al, 2005).


  • By transplanting single VESC into normal mice, functional donor derived blood vessels consisting of portal veins, sinusoids, and hepatic venules are generated.
  • VESCs maintain large vessels and sinusoids in the normal mice liver for more than a year.
  • VESC collected from healthy mice are injected into mice with hemophilia A, the cells began generating new liver blood vessels and the level of FVIII in the blood shot up, from less than 1% of normal to over 60%.


Prof. Nobuyuki Takakura (Osaka University)

Patent status

PCT application (unpublished)


Cell Stem Cell. 2018 Mar 1;22(3):384-397.e6.

Circ J. 2018 Dec 25;83(1):12-17.


We are looking for a company interested in commercial development of the therapeutics. Details can be disclosed under CDA. Patent licensing are available.

Product No: CD-02377

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name


Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.


Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Bionauts.jp Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.